Literature DB >> 1267430

Hyperbaric oxygen exposures for intrahepatic abscesses produced in mice by nonsporeforming anaerobic bacteria.

G B Hill.   

Abstract

Hyperbaric oxygen exposures were evaluated for treatment of progressive liver abscesses produced by intraperitoneal injection of combined cultures of Fusobacterium necrophorum plus either Bacteroides fragilis subsp. fragilis or Fusobacterium nucleatum in a mouse model. Infected control and hyperbaric oxygen-exposed mice were autopsied 5 or 6 weeks after inoculation of bacteria and were assigned numerical pathology scores according to the number and size of abscesses present. Seventeen daily 3-h exposures to 100% O(2) at 2 atmospheres absolute pressure begun either 1 day or 1 week after injection of bacteria significantly reduced the number and size of abscesses among mice infected with either mixture of anaerobic organisms. Abscesses due to mixed fusobacteria were often completely resolved. These data support the efficacy of hyperbaric oxygen for treatment of mixed anaerobic infection produced by Bacteroides and Fusobacterium species and suggest its further evaluation as a potential alternate or adjunct to present therapy for certain types of serious anaerobic infection.

Entities:  

Mesh:

Year:  1976        PMID: 1267430      PMCID: PMC429520          DOI: 10.1128/AAC.9.2.312

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  INHIBITION OF TOXIN PRODUCTION IN CLOSTRIDIUM PERFRINGENS IN VITRO BY HYPERBARIC OXYGEN.

Authors: 
Journal:  Antonie Van Leeuwenhoek       Date:  1965       Impact factor: 2.271

2.  Experimental and clinical experience with hyperbaric oxygen in the treatment of clostridial myonecrosis.

Authors:  J A Holland; G B Hill; W G Wolfe; S Osterhout; H A Saltzman; I W Brown
Journal:  Surgery       Date:  1975-01       Impact factor: 3.982

Review 3.  Anaerobic infections (third of three parts).

Authors:  S L Gorbach; J G Bartlett
Journal:  N Engl J Med       Date:  1974-06-06       Impact factor: 91.245

Review 4.  Anaerobic pyogenic liver abscess.

Authors:  J Sabbaj; V L Sutter; S M Finegold
Journal:  Ann Intern Med       Date:  1972-10       Impact factor: 25.391

5.  Experimental effects of hyperbaric oxgen on selected clostridial species. I. In-vitro studies.

Authors:  G B Hill; S Osterhout
Journal:  J Infect Dis       Date:  1972-01       Impact factor: 5.226

6.  Hyperbaric oxygen therapy in bacteroides infections.

Authors:  A Schreiner; S Tönjum; A Digranes
Journal:  Acta Chir Scand       Date:  1974

Review 7.  Anaerobic bacteria of the gastrointestinal flora and their occurrence in clinical infections.

Authors:  W E Moore; E P Cato; L V Holdeman
Journal:  J Infect Dis       Date:  1969-06       Impact factor: 5.226

8.  Variation in response to hyperbaric oxygen among inbred strains of mice.

Authors:  G B Hill; S Osterhout; W M O'Fallon
Journal:  Proc Soc Exp Biol Med       Date:  1968-12

9.  Management of anaerobic infections.

Authors:  S M Finegold; J G Bartlett; A W Chow; D J Flora; S L Gorbach; E J Harder; F P Tally
Journal:  Ann Intern Med       Date:  1975-09       Impact factor: 25.391

10.  Liver abscess production by non-spore-forming anaerobic bacteria in a mouse model.

Authors:  G B Hill; S Osterhout; P C Pratt
Journal:  Infect Immun       Date:  1974-03       Impact factor: 3.441

View more
  3 in total

1.  Closure of refractory perineal Crohn's lesion. Integration of hyperbaric oxygen into case management.

Authors:  E W Nelson; D E Bright; L F Villar
Journal:  Dig Dis Sci       Date:  1990-12       Impact factor: 3.199

2.  Adjunctive hyperbaric oxygen therapy for actinomycotic lacrimal canaliculitis.

Authors:  Y Shauly; Z Nachum; M Gdal-On; Y Melamed; B Miller
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-07       Impact factor: 3.117

Review 3.  Hyperbaric Oxygen Therapy in Liver Diseases.

Authors:  Yun Sun; Yankai Wen; Chanjuan Shen; Yuanrun Zhu; Wendong You; Yuanyuan Meng; Lijuan Chen; Yiping Feng; Xiaofeng Yang; Zuo-Bing Chen
Journal:  Int J Med Sci       Date:  2018-05-22       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.